CN107137695A - Carbetocin is used for the purposes for preparing medicament for treatment of depression - Google Patents
Carbetocin is used for the purposes for preparing medicament for treatment of depression Download PDFInfo
- Publication number
- CN107137695A CN107137695A CN201710496206.1A CN201710496206A CN107137695A CN 107137695 A CN107137695 A CN 107137695A CN 201710496206 A CN201710496206 A CN 201710496206A CN 107137695 A CN107137695 A CN 107137695A
- Authority
- CN
- China
- Prior art keywords
- depression
- carbetocin
- medicine
- treatment
- oxytocins
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/095—Oxytocins; Vasopressins; Related peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention belongs to technical field of medicine, and in particular to a kind of carbetocin is used for the purposes for preparing medicament for treatment of depression.Scheme of the present invention is using oxytocin and the like as the active component for preparing medicament for treatment of depression, and the symptoms such as depression can effectively be treated to a certain extent by inquiring into and demonstrating it.Carbetocin is the Oxitocin analogues of nonapeptide, experiment shows, carbetocin can effectively invert tree shrew by stress after it is increased escape electric shock error number, the syrup preference of decline and the social interaction time of reduction, there is therapeutic action to behavior depression, new medicinal usage is provided for the application of carbetocin, while also providing new treatment means for the treatment of depression.
Description
Technical field
The invention belongs to technical field of medicine, and in particular to a kind of carbetocin is used to prepare treatment depression medicine
The purposes of thing.
Background technology
Depression is a kind of mode of onset of manic-depressive psychosis, is subtracted with the action of hypothymergasia, retardation of thinking and speech
Few, slow is classical symptom.Depression seriously perplexs the live and work of patient, and white elephant is brought to family and society,
The patients with depression that there are about 15% according to statistics dies from suicide.According to Chinese Spirit Obstacles classification and the diagnostic criteria third edition (CCMD-
3) hypodepression or major depression, can be divided into according to the degree depression damaged to social function；According to whether there is illusion,
Vain hope, or the psychotic symptoms such as tonic symptoms, depression are divided into the depression for the characteristic of disease symptom that is a cup too low and are mentally ill again
The depression of property symptom；According to whether having another paralepsy (before at least two month of interval) before, depression is divided into head again
Send out depression and recurrent major depression.Shown according to the World Health Organization, the World Bank and Harvard University joint study,
Depression has become the second serious disease of Chinese Disease Spectrum.
It is considered as the important indicator for diagnosing depression that anhedonia, Xi Zezong and society, which avoid,.Antidepressants
(antidepressive drugs) refers to that one group is mainly used to treatment to be in a very depressed state as the essence of the mental illness of prominent symptom
God's medicine thing, is a major class of numerous psychotropic agents, is mainly used in treatment depression and various depressive states.It is different from stimulant
Part can not improve the mood of normal person for that can only eliminate the depressive symptom of depressed patient.Antidepressants are in 20th century
The fifties comes out, and has no suitable class of medications in depressive illness before this, often relies on electro-shock therapy.50 years 20th century
After generation, antidepressants turn into the preferred treatment means of depressed patient, largely instead of shock treatment.Common
Generation antidepressant has two kinds, i.e. MAOI (MAOI) and tricyclic antidepressant (TCA).Although due to new
Medicine have developed rapidly, and new drug emerges in an endless stream, such as ten thousand daraf(reciprocal of farad) stars, nefazodone, but at present still with selective serotonin (5-HT)
Based on reuptake suppression agent, this kind of medicine of clinical practice is also at most most wide.
Oxytocins is a kind of hypophysis neurohormone medicine, and it is fast that research shows that oxytocins can make it produce in zoopery
Sense (Melis et al., 2007), also contributes to adjust social action in clinic, such as sets up society's connection, carries out positive
Communication etc. (De Dreu et al., 2011)；Meanwhile, oxytocins can also act on endocrine simultaneously in terms of neuromechanism
System and monoamine transmitterses system.At present, relevant oxytocins is used for not yet having related report in terms for the treatment of the mental illnesses such as depression
Road.
The content of the invention
Therefore, the technical problems to be solved by the invention be to provide a kind of carbetocin be used for prepare treat depression
The new application of medicine.
In order to solve the above technical problems, being used to prepare treatment depression the invention discloses described oxytocins and the like
The purposes of medicine.
It is preferred that, the oxytocins includes carbetocin.
The invention also discloses a kind of medicine for being used to treat depression, the medicine is based on oxytocins and the like
Want active component.
It is preferred that, the oxytocins is carbetocin.
More excellent, the amount containing carbetocin in the pharmaceutical units preparation is 150- according to amount of formulation is taken day
Calculate within 200mg/ days.
Unit formulation of the present invention refers to that every capsule of capsule formulation, tablet are per tablet preparation, injection 10ml/
The 25g/ bags of branch or granule.
The medicine adds customary adjuvant according to common process, and clinically acceptable oral preparations are made.
Specifically, the preparation includes tablet, capsule, pill, pill, granule, powder.
The auxiliary material is included in filler, disintegrant, lubricant, adhesive, flavouring, suspending agent, preservative or matrix
One or more of mixtures.
The filler include but is not limited to starch, pregelatinized starch, lactose, mannitol, chitin, microcrystalline cellulose,
One or more mixtures in sucrose；
The disintegrant includes but is not limited to starch, PVPP, hydroxypropyl cellulose, sodium carboxymethylcellulose, carboxylic
One or more mixtures in methyl starch sodium；
One kind that the lubricant includes but is not limited in magnesium stearate, talcum powder, silica, lauryl sodium sulfate
Or a variety of mixtures；
The suspending agent includes but is not limited to polyvinylpyrrolidone, microcrystalline cellulose, sucrose, agar, hydroxypropyl methyl
One or more mixtures in cellulose；
One kind that described adhesive includes but is not limited in starch slurry, polyvinylpyrrolidone, hydroxypropyl methyl cellulose
Or a variety of mixtures；
The flavouring includes but is not limited to sweetener and/or essence；The sweetener is saccharin sodium, aspartame, sugarcane
One or more mixtures in sugar, honey element；
The preservative include but is not limited in parabens, benzoic acid, sodium benzoate, sorbic acid, sorbate one
Plant or a variety of mixtures；
The matrix includes the mixture of one or both of PEG, insect wax.
It should be noted that the customary adjuvant includes but is not limited to the above-mentioned scope enumerated, those skilled in the art can
The selection and adjustment of adaptability are done according to actual conditions.
The invention also discloses a kind of method for preparing the medicine, i.e., each raw material components are measured according to selected prescription,
Selected auxiliary material is added, clinically acceptable formulation is made according to common process.
Scheme of the present invention is inquired into using oxytocin and the like as the active component for preparing medicament for treatment of depression
And demonstrate it and can effectively treat the symptoms such as depression to a certain extent.Carbetocin is the Oxitocin analogues of nonapeptide,
Experiment shows, carbetocin can effectively invert tree shrew by stress after it is increased escape electric shock error number, the syrup of decline is inclined
Love and the social interaction time of reduction, there is therapeutic action to behavior depression, provided newly for the application of carbetocin
Medicinal usage, while also providing new treatment means for the treatment of depression.
Brief description of the drawings
In order that present disclosure is more likely to be clearly understood, specific embodiment and combination below according to the present invention
Accompanying drawing, the present invention is further detailed explanation, wherein,
Fig. 1 is influence result of the chronic stress of the present invention for tree shrew behavior depression；Wherein, A is chronic stress behavior
Experiment flow；B is that stress group shows more to escape failure behavior compared to non-stress group；C is that stress group is shown less
The social interaction time；D is that stress group shows lower syrup preference fraction；Control group N=9, stress group N=13, * p<
0.05、**p<0.01 compared to control group, ##p<0.01 surveys compared to preceding；
Fig. 2 is treatment results of the drug therapy of the present invention for behavior depression caused by chronic stress；Wherein, A is use
Each experimental group shows the escape number of shocks of reduction after medicine；B is each experimental group increase syrup preference fraction after medication；C is use
Each experimental group increased social interaction time after medicine；Every group of N=3, * p<0.05, * * p<0.01 with the stress group through saline treatment
Compare, #p<0.05, ##p<0.01 compared with control group.
Embodiment
The tablet of embodiment 1
Take carbetocin 100g, the starch of dosage of getting it filled, talcum powder, microcrystalline cellulose, hydroxypropyl methyl cellulose and
Sucrose is auxiliary material, and tablet is made according to common process.It is 100mg per content of the tablet preparation containing carbetocin, 1 tablet once, often
Day 2 times.
The capsule of embodiment 2
Carbetocin 100g is taken, microcrystalline cellulose, PVPP, magnesium stearate, the polyvinyl pyrrole of dosage of getting it filled
Alkanone, sorbic acid are auxiliary material, and capsule is made according to common process.Content of the every capsule containing carbetocin is 50mg,
2 every time, 2 times a day.
The granule of embodiment 3
Take carbetocin 100g, the starch of dosage of getting it filled, PVPP, magnesium stearate, sucrose, supplemented by sorbic acid
Material, granule is made according to common process.Every bag of particle dosage is 25g, and the content containing carbetocin is 100mg, every time 1
Bag, 2 times a day.
Experimental example
1st, chronic stress makes tree shrew produce behavior depression
Show according to the study, the important diagnostic symptom that helplessness, society are avoided and anhedonia is depression.Therefore, I
Will escape respectively the frequency of failure of electric shock, social interaction time and syrup have a preference for number of times as helplessness, society avoid with
And the behavior judge index of anhedonia.
Using chronic stress mode to tree shrew carry out three weeks stress, specifically include：It is chronic unpredictable by two weeks
Stress, and the foot shock of one week, specific chronic stress flow is shown in A in accompanying drawing 1.
Stress tests result shows, the result as shown in B in accompanying drawing 1, compared to do not live through it is above-mentioned stress tree shrew,
Stress after tree shrew show the escape frequency of failure substantially risen, it is meant that by stress helplessness rise；As in accompanying drawing 1
Result shown in C, compared to do not live through it is above-mentioned stress tree shrew, stress after the tree shrew social interaction time be decreased obviously,
Show that tree shrew generates social avlidance behavior；Result as shown in D in accompanying drawing 1, compared to do not live through it is above-mentioned stress tree
Shrew, stress after tree shrew syrup preference is decreased obviously, show that tree shrew stress anhedonia afterwards.Result above illustrates to pass through three
Week stress after, tree shrew shows obvious behavior depression.
2nd, carbetocin has obvious therapeutic effect to behavior depression
On the basis of behavior depression is established, card shellfish contracting palace is given with the dosage of daily 20mg/kg body weight to tree shrew
Element, is administered treatment 2 weeks, then detects its therapeutic effect for behavior depression.Meanwhile, this research also makes on tree shrew
With classical antidepressant fluoxetine as positive control (15mg/kg), non-administered group is used as using salt solution.
As A in Fig. 2 and the result shown in B are shown, compared to non-administered group (salt solution group), carbetocin is equal with Prozac
Can effectively invert tree shrew by stress after it is increased escape electric shock error number, decline syrup preference and reduction social interaction
Time, show that two kinds of medicines have therapeutic action to behavior depression；Result as shown in C in Fig. 2 is shown, in social interaction
In test, the therapeutic effect of carbetocin is higher than Prozac, and this result shows that carbetocin avoids this in society
There is more preferable curative effect in behavior depression, this also indicates that carbetocin has in the society of patients with depression avoids this symptom
More preferable therapeutic effect.
Obviously, above-described embodiment is only intended to clearly illustrate example, and the not restriction to embodiment.It is right
For those of ordinary skill in the art, can also make on the basis of the above description it is other it is various forms of change or
Change.There is no necessity and possibility to exhaust all the enbodiments.And the obvious change thus extended out or
Among changing still in the protection domain of the invention.
Claims (9)
1. oxytocins and the like is used for the purposes for preparing medicament for treatment of depression.
2. purposes according to claim 1, it is characterised in that the oxytocins includes carbetocin.
3. a kind of medicine for being used to treat depression, it is characterised in that the medicine is main living with oxytocins and the like
Property composition.
4. medicine according to claim 3, it is characterised in that the oxytocins is carbetocin.
5. medicine according to claim 4, it is characterised in that the amount containing carbetocin in the pharmaceutical units preparation,
Calculated according to amount of formulation is taken day for 150-200mg/ days.
6. the medicine according to claim 4 or 5, it is characterised in that the medicine adds customary adjuvant according to common process,
Clinically acceptable oral preparations are made.
7. medicine according to claim 6, it is characterised in that the preparation include tablet, capsule, pill, pill,
Granule, powder.
8. the medicine according to claim 6 or 7, it is characterised in that the auxiliary material include filler, disintegrant, lubricant,
One or more of mixtures in adhesive, flavouring, suspending agent, preservative or matrix.
9. a kind of method for preparing any one of the claim 3-8 medicines, it is characterised in that measured respectively according to selected prescription
Raw material components, add selected auxiliary material, clinically acceptable formulation are made according to common process.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710496206.1A CN107137695A (en) | 2017-06-26 | 2017-06-26 | Carbetocin is used for the purposes for preparing medicament for treatment of depression |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710496206.1A CN107137695A (en) | 2017-06-26 | 2017-06-26 | Carbetocin is used for the purposes for preparing medicament for treatment of depression |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107137695A true CN107137695A (en) | 2017-09-08 |
Family
ID=59784223
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710496206.1A Pending CN107137695A (en) | 2017-06-26 | 2017-06-26 | Carbetocin is used for the purposes for preparing medicament for treatment of depression |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107137695A (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101677948A (en) * | 2007-06-07 | 2010-03-24 | 纳斯泰克制药公司 | Intranasal carbetocin formulations and the autistic method of treatment |
-
2017
- 2017-06-26 CN CN201710496206.1A patent/CN107137695A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101677948A (en) * | 2007-06-07 | 2010-03-24 | 纳斯泰克制药公司 | Intranasal carbetocin formulations and the autistic method of treatment |
Non-Patent Citations (2)
| Title |
|---|
| XIAOLU MENG等: "Depression-like behaviors in tree shrews and comparison of the effects of treatment with fluoxetine and carbetocin", 《PHARMACOLOGY, BIOCHEMISTRY AND BEHAVIOR》 * |
| 吴华波等: "催产素及受体基因在抑郁症治疗中的潜在作用", 《现代生物医学进展》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20140093592A1 (en) | Esketamine for the treatment of treatment-refractory or treatment-resistant depression | |
| US8703823B2 (en) | Methods for treatment of migraine and symptoms thereof | |
| JP2015516395A (en) | New method | |
| EA014189B1 (en) | Use of flibanserin for the treatment of pre-menopausal sexual desire disorders | |
| US11065213B2 (en) | Amantadine compositions and preparations thereof | |
| TWI826380B (en) | Nk-1 antagonist compositions and methods for use in treating depression | |
| RU2268725C2 (en) | Combination of medicinal agents comprising mirtazapine for treatment of depression and associated disorders | |
| Hartshorn et al. | Adverse effects and drug interactions associated with fluoxetine therapy | |
| MX2014002125A (en) | Treatment of symptoms associated with female gastroparesis. | |
| Hammer | Effect of repeated capsaicin ingestion on intestinal chemosensation and mechanosensation | |
| JP2024010018A (en) | Compositions and method for treating depression | |
| CN107137695A (en) | Carbetocin is used for the purposes for preparing medicament for treatment of depression | |
| CN104510854B (en) | A kind of Chinese medicine composition for the treatment of dysmenorrhes and uses thereof | |
| CN103860532A (en) | Memantine-metformin compound medicinal composition and preparation method thereof | |
| CN104000815B (en) | A kind of pharmaceutical composition containing Esomeprazole and application thereof | |
| CN108478567A (en) | Novel pharmaceutical formulation | |
| US20230089848A1 (en) | Psilocybin derived compositions and methods using same | |
| US7842702B2 (en) | Treatment for irritable bowel syndrome | |
| JP5042425B2 (en) | Tramadol for the treatment of functional gastrointestinal diseases | |
| BIKASH et al. | TREATMENT OF IRRITABLE BOWEL SYNDROME: A REVIEW | |
| JPH07503972A (en) | Brophalomine as a drug for the treatment of post-traumatic stress | |
| CN103585411A (en) | Medicament for treating haemorrhoids | |
| JPS6116A (en) | Improvement on organic compound | |
| Watcha et al. | 9 Antiemetics | |
| CN107260718A (en) | Verapamil is used to prepare the purposes for suppressing to relapse medicine after drug rehabilitation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170908 |
|
| RJ01 | Rejection of invention patent application after publication |